Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequential Therapy Clear all
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736, PLACEBO
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

NCT00792142
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Interventions
bortezomib, dexamethasone, melphalan, thalidomide, cytogenetic analysis, fluorescence in situ hybridization, laboratory biomarker analysis, questionnaire administration, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

New Individualized Therapy Trial for Metastatic Colorectal Cancer

NCT00867334
View directory record Official record
Conditions
Colorectal Neoplasm, Colorectal Cancer
Interventions
Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 29, 2026, 1:19 PM EDT
Not yet recruiting Phase 1 Interventional

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

NCT06461676
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Ventrix Bio Extracellular Matrix
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 29, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

NCT07074756
View directory record Official record
Conditions
Glioma, Recurrent Glioma, Recurrent Glioblastoma
Interventions
Chemotherapy, Computed Tomography, Internet-Based Intervention, Magnetic Resonance Imaging, Neurologic Examination, Questionnaire Administration, Surveillance, Propranolol, Imipramine, Bevacizumab
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RF Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite

NCT06283056
View directory record Official record
Conditions
Cellulitis of Leg
Interventions
Device treatment
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Withdrawn Phase 4 Interventional

Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

NCT04730609
View directory record Official record
Conditions
Shivering, Dose Finding Study
Interventions
Dexmedetomidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

NCT01290471
View directory record Official record
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

NCT00728793
View directory record Official record
Conditions
Tumors
Interventions
CUDC-101
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 29, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome

NCT02461095
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Impairment based approach, PFPS Algorithm approach
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Columbus, Ohio • Dublin, Ohio • New Albany, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

NCT05781399
View directory record Official record
Conditions
Phenylketonuria
Interventions
JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Not listed Not applicable Interventional

Concurrent Treatment for Patients With Cervical Radiculopathy

NCT03636009
View directory record Official record
Conditions
Spinal Nerve Root Disorder Nos
Interventions
concurrent traction and neuromobilization technique, sequential traction and neuromobilization technique, active exercise program, manual therapy to cervical and thoracic spine
Other
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 29, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19

NCT04748783
View directory record Official record
Conditions
COVID19, Coronavirus Infection, SARS CoV-2 Infection
Interventions
Water, Peroxyl, Periogard, Colgate Total Zero
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

TOlerability of Transcranial Direct Current Stimulation in Pediatric Stroke Survivors

NCT05812794
View directory record Official record
Conditions
Childhood Stroke
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 29, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

NCT02910882
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
Drug · Radiation
Lead sponsor
Scripps Health
Other
Eligibility
Up to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies

NCT02340728
View directory record Official record
Conditions
Pancreatic Cancer, Unresectable Biliary-pancreatic Malignancies
Interventions
ERCP with SEMS plus radiofrequency ablation, ERCP with SEMS alone (standard of care)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 29, 2026, 1:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

NCT02572973
View directory record Official record
Conditions
Separation Anxiety Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions
Acoustic Neuromodulation (ANM)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 29, 2026, 1:19 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Floatation Experience in Nurses and Physicians

NCT05977894
View directory record Official record
Conditions
Burnout, Professional, Negative Affect, Positive Affect, Wellbeing, Burnout, Psychological
Interventions
Reduced Environmental Stimulation Therapy
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT04243083
View directory record Official record
Conditions
Healthy
Interventions
TLL018 tablet, placebo
Drug
Lead sponsor
TLL Pharmaceutical, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 29, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg)
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 29, 2026, 1:19 PM EDT
Active, not recruiting Phase 4 Interventional

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

NCT06986603
View directory record Official record
Conditions
Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions
Glucagon for Injection (Fresenius Kabi USA)
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 29, 2026, 1:19 PM EDT